DRUG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Bright Minds Biosciences (DRUG)
NEW YORK CITY, NY / ACCESS Newswire / November 4, 2026 / Investors holding Bright Minds Biosciences (NASDAQ:DRUG) are absorbing losses after a sharp selloff triggered by the FDA's partial clinical hold on the Company's planned Phase 2 BMB-101 trial in developmental and epileptic encephalopathies (DEE). If you bought DRUG shares and lost money when the stock sold off, you may have legal rights. Shareholders who suffered losses are encouraged to submit their DRUG loss information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
For DRUG holders, the hold has created uncertainty over the planned trial's design, timing, and regulatory path. Bright Minds stated that the hold applies only to the planned U.S. study and does not affect its other ongoing clinical trials. The Company also said it disagrees with the FDA's interpretation of the mouse findings, but that disagreement did not resolve the agency's concerns.
Bright Minds has said it is awaiting the FDA's full letter. The Company acknowledged that additional data or studies may be required to address the agency's concerns. Levi & Korsinsky is investigating potential securities law violations on behalf of DRUG investors who lost money in the selloff.
If you lost money on Bright Minds Biosciences stock, request a review of your DRUG losses or call (212) 363-7500 today.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the DRUG Investigation
Q: How much did DRUG stock drop? A: Bright Minds Biosciences shares sold off sharply after the Company disclosed that the FDA had placed its planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. Individual losses depend on each investor's purchase price and timing. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Bright Minds Biosciences made materially false or misleading statements regarding BMB-101 and the regulatory path for its planned Phase 2 pediatric epilepsy trial. When the Company disclosed that the FDA had placed the planned trial on partial clinical hold, the stock price declined sharply.
Q: When did Bright Minds Biosciences allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.
Q: What do DRUG investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my DRUG shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought DRUG and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP